Zobrazeno 1 - 10
of 50
pro vyhledávání: '"Roni Weisshof"'
Autor:
Roni Weisshof, Stephan R. Vavricka, Lieven Pouillon, Fiona Braegger, Montserrat Roset, Nawal Bent-Ennakhil, Marc Ferrante
Publikováno v:
BMC Gastroenterology, Vol 23, Iss 1, Pp 1-12 (2023)
Abstract Background Vedolizumab (VDZ), a gut-selective anti-lymphocyte trafficking integrin antibody, is effective in treating patients with moderately to severely active Crohn’s disease (CD). In this study, we examined the real-world effectiveness
Externí odkaz:
https://doaj.org/article/293bb4dc730a434ebcc8bc6dfd6983d2
Publikováno v:
Revista Médica Clínica Las Condes, Vol 30, Iss 5, Pp 339-343 (2019)
This article describes the need for objective treatment and management goals of inflammatory bowel disease to monitor disease course and progression. We discuss the “treat to target” or “tight control” approach as an evolving treatment strate
Externí odkaz:
https://doaj.org/article/7997b25a54254aecb539b4d09e5fb50e
Autor:
Liran I Shlush, Gil Atzmon, Roni Weisshof, Doron Behar, Guenady Yudkovsky, Nir Barzilai, Karl Skorecki
Publikováno v:
PLoS ONE, Vol 3, Iss 10, p e3425 (2008)
BACKGROUND: Association of mitochondrial haplogroup J with longevity has been reported in several population subgroups. While studies from northern Italy and Finland, have described a higher frequency of haplogroup J among centenarians in comparison
Externí odkaz:
https://doaj.org/article/09d65a3b497c4337812f74ef37aa49dd
Autor:
Netta Glaubach, Dana Ben Hur, Alexander Korytny, Yoni Isenberg, Yousef Laham, Ronit Almog, Irit Chermesh, Roni Weisshof, Haggai Bar-Yoseph
Publikováno v:
Digestive Diseases and Sciences. 68:2180-2187
Autor:
Leonard Haas, Paul Nagy, Mary Bowring, Michael Cook, Ramit Magen-Rimon, Roni Weisshof, Chen Yanover, Steven Miller
Publikováno v:
Inflammatory Bowel Diseases. 29:S34-S35
BACKGROUND Inflammatory Bowel Disease (IBD) is an increasingly prevalent condition that results in weight loss, bloody diarrhea, and poor quality of life. Traditional population-based research on patients with IBD has involved use of relatively shall
Autor:
Marc Ferrante, Stephan R. Vavricka, L Pouillon, Roni Weisshof, M Roset, F Braegger, Nawal Bent-Ennakhil
Publikováno v:
Journal of Crohn's and Colitis. 15:S317-S319
Background The α4β7 integrin monoclonal antibody vedolizumab (VDZ) has been shown to be efficacious for patients with moderate-to-severe Crohn’s disease (CD). This study aimed to analyse the added value of budesonide in combination with VDZ as an
Autor:
Henit Yanai, Anna Kagramanova, Oleg Knyazev, João Sabino, Shana Haenen, Gerassimos J Mantzaris, Katerina Mountaki, Alessandro Armuzzi, Daniela Pugliese, Federica Furfaro, Gionata Fiorino, David Drobne, Tina Kurent, Sharif Yassin, Nitsan Maharshak, Fabiana Castiglione, Roberto de Sire, Olga Maria Nardone, Klaudia Farkas, Tamas Molnar, Zeljko Krznaric, Marko Brinar, Elena Chashkova, Moran Livne Margolin, Uri Kopylov, Cristina Bezzio, Ariella Bar-Gil Shitrit, Milan Lukas, María Chaparro, Marie Truyens, Stéphane Nancey, Triana Lobaton, Javier P Gisbert, Simone Saibeni, Péter Bacsúr, Peter Bossuyt, Julien Schulberg, Frank Hoentjen, Chiara Viganò, Andrea Palermo, Joana Torres, Joana Revés, Konstantinos Karmiris, Magdalini Velegraki, Edoardo Savarino, Panagiotis Markopoulos, Eftychia Tsironi, Pierre Ellul, Cristina Calviño Suárez, Roni Weisshof, Dana Ben-Hur, Timna Naftali, Carl Eriksson, Ioannis E Koutroubakis, Kalliopi Foteinogiannopoulou, Jimmy K Limdi, Eleanor Liu, Gerard Surís, Emma Calabrese, Francesca Zorzi, Rafał Filip, Davide Giuseppe Ribaldone, Yifat Snir, Idan Goren, Hagar Banai-Eran, Yelena Broytman, Hadar Amir Barak, Irit Avni-Biron, Jacob E Ollech, Iris Dotan, Maya Aharoni Golan
Publikováno v:
Journal of Crohn's and Colitis, 16, 12, pp. 1882-1892
JOURNAL OF CROHNS & COLITIS
Journal of Crohn's and Colitis, 16, 1882-1892
JOURNAL OF CROHNS & COLITIS
Journal of Crohn's and Colitis, 16, 1882-1892
Background Endoscopic-post-operative-recurrence [ePOR] in Crohn’s disease [CD] after ileocecal resection [ICR] is a major concern. We aimed to evaluate the effectiveness of early prophylaxis with biologics and to compare anti-tumour necrosis factor
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ed228cfd6a620d61ff07d1f9be9ff326
https://repository.ubn.ru.nl/handle/2066/288021
https://repository.ubn.ru.nl/handle/2066/288021
Autor:
Stefano Festa, Uri Kopylov, Marie Truyens, Bas Oldenburg, Nanne K. H. de Boer, Lena Capirchio, Edoardo Savarino, Ahmad Albshesh, Rafał Filip, Eirini Theodoraki, Gabriele Dragoni, Michel H. Maillard, Piotr Eder, Roni Weisshof, Gerassimos J. Mantzaris, Davide Giuseppe Ribaldone
Publikováno v:
Journal of Crohn's & colitis, 16(1), 91-97. Elsevier
Albshesh, A, Eder, P, Ribaldone, D G, Oldenburg, B, de Boer, N K, Mantzaris, G J, Savarino, E V, Dragoni, G, Weisshof, R, Truyens, M, Festa, S, Maillard, M H, Capirchio, L, Filip, R, Theodoraki, E & Kopylov, U 2022, ' Primary Hypogammaglobulinaemia with Inflammatory Bowel Disease-Like Features : An ECCO CONFER Multicentre Case Series ', Journal of Crohn's & colitis, vol. 16, no. 1, pp. 91-97 . https://doi.org/10.1093/ecco-jcc/jjab124
JOURNAL OF CROHNS & COLITIS
Albshesh, A, Eder, P, Ribaldone, D G, Oldenburg, B, de Boer, N K, Mantzaris, G J, Savarino, E V, Dragoni, G, Weisshof, R, Truyens, M, Festa, S, Maillard, M H, Capirchio, L, Filip, R, Theodoraki, E & Kopylov, U 2022, ' Primary Hypogammaglobulinaemia with Inflammatory Bowel Disease-Like Features : An ECCO CONFER Multicentre Case Series ', Journal of Crohn's & colitis, vol. 16, no. 1, pp. 91-97 . https://doi.org/10.1093/ecco-jcc/jjab124
JOURNAL OF CROHNS & COLITIS
Background Hypogammaglobulinaemia is a disorder characterized by low serum immunoglobulin levels and a high prevalence of gastrointestinal manifestations. In some cases, clinical and endoscopic features are indistinguishable from those of inflammator
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0fa35fe48f0ca1f1b46a24a4afca6eed
https://research.vumc.nl/en/publications/c912aa1c-f626-49c9-8d37-8f8d923fd727
https://research.vumc.nl/en/publications/c912aa1c-f626-49c9-8d37-8f8d923fd727
Autor:
Irit Avni-Biron, Ariella Bar-Gil Shitrit, Benjamin Koslowsky, Asaf Levartovsky, Uri Kopylov, Roni Weisshof, Nathaniel Aviv Cohen, Nitsan Maharshak, David Hovel, Eran Israeli, Timna Naftali, Idan Goren, Yfat Snir, Jacob E. Ollech, Hagar Banai-Eran, Yelena Broitman, Tali Sharar-Fischler, Iris Dotan, Henit Yanai
Publikováno v:
Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver. 54(2)
We sought to define the effectiveness and safety of tofacitinib in a real-world (RW) cohort of Israeli patients with moderate to severe ulcerative colitis (UC).This was a multi-center retrospective observational cohort study (2019-2020) to assess the
Publikováno v:
Alimentary pharmacologytherapeuticsREFERENCES. 54(1)